CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
0.7135
4.21%
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.0066
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001151%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.6847
Open 0.7191
1-Year Change -42%
Day's Range 0.7 - 0.7353
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 23, 2025 0.7135 0.0166 2.38% 0.6969 0.7435 0.6969
Apr 22, 2025 0.6847 0.0118 1.75% 0.6729 0.6999 0.6729
Apr 21, 2025 0.6740 0.0091 1.37% 0.6649 0.6779 0.6499
Apr 17, 2025 0.6789 0.0290 4.46% 0.6499 0.6850 0.6499
Apr 16, 2025 0.6509 -0.0192 -2.87% 0.6701 0.6701 0.6354
Apr 15, 2025 0.6951 0.0182 2.69% 0.6769 0.7069 0.6610
Apr 14, 2025 0.6706 -0.0382 -5.39% 0.7088 0.7355 0.6519
Apr 11, 2025 0.6832 0.0163 2.44% 0.6669 0.7289 0.6354
Apr 10, 2025 0.6694 -0.0038 -0.56% 0.6732 0.6734 0.6368
Apr 9, 2025 0.6897 0.1094 18.85% 0.5803 0.7143 0.5669
Apr 8, 2025 0.5795 -0.0544 -8.58% 0.6339 0.6521 0.5788
Apr 7, 2025 0.6368 0.0399 6.68% 0.5969 0.6625 0.5769
Apr 4, 2025 0.6587 0.0528 8.71% 0.6059 0.6853 0.6037
Apr 3, 2025 0.6355 -0.0120 -1.85% 0.6475 0.6616 0.6169
Apr 2, 2025 0.6829 0.0360 5.57% 0.6469 0.7069 0.6269
Apr 1, 2025 0.6440 -0.0429 -6.25% 0.6869 0.7136 0.6318
Mar 31, 2025 0.6984 -0.0440 -5.93% 0.7424 0.7605 0.6769
Mar 28, 2025 0.7901 0.0882 12.57% 0.7019 0.7960 0.6970
Mar 27, 2025 0.7170 -0.0194 -2.63% 0.7364 0.7364 0.6870
Mar 26, 2025 0.7332 0.0063 0.87% 0.7269 0.7347 0.6998

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ocugen, Inc. Company profile

Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine. 

Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.

Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. 

For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.

The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).

The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). 

Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.

Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.

Ocugen is headquartered in Malvern, Pennsylvania.

Industry: Biotechnology & Medical Research (NEC)

11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US

People also watch

XRP/USD

2.20 Price
+1.910% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01097

BTC/USD

93,014.60 Price
+2.110% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

Gold

3,322.82 Price
-1.710% 1D Chg, %
Long position overnight fee -0.0170%
Short position overnight fee 0.0088%
Overnight fee time 21:00 (UTC)
Spread 0.30

ETH/USD

1,782.47 Price
+5.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 720,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading